Abstract: The present invention relates to a therapeutic agent for pulmonary hypertension comprising an interleukin-5 receptor (hereinafter, abbreviated to “IL-5R”)-inhibiting compound and therapeutic method therefor. More specifically, the present invention relates to a therapeutic agent for pulmonary hypertension comprising an antibody or an antibody fragment capable of specifically binding to the extracellular region of IL-5R and a therapeutic method therefor.

Abstract: The present invention relates to a therapeutic agent for pulmonary hypertension comprising an interleukin-5 receptor (hereinafter, abbreviated to “IL-5R”)-inhibiting compound and therapeutic method therefor. More specifically, the present invention relates to a therapeutic agent for pulmonary hypertension comprising an antibody or an antibody fragment capable of specifically binding to the extracellular region of IL-5R and a therapeutic method therefor.

Abstract: The present invention provides monoclonal antibodies and humanized antibodies which react specifically with a human interleukin-5 receptor ? chain. The invention also provides hybridomas and transformants which produce the antibodies, the monoclonal antibodies and humanized antibodies, a method for detecting an interleukin-5 receptor ? chain immunologically by means of these antibodies, as well as a method for diagnosing and treating diseases such as chronic bronchial asthma by means of the monoclonal antibodies and humanized antibodies. The present invention is useful for diagnosis or treatment of diseases such as chronic bronchial asthma.

Abstract: The present invention provides monoclonal antibodies and humanized antibodies which react specifically with a human interleukin-5 receptor ? chain. The invention also provides hybridomas and transformants which produce the antibodies, the monoclonal antibodies and humanized antibodies, a method for detecting an interleukin-5 receptor ? chain immunologically by means of these antibodies, as well as a method for diagnosing and treating diseases such as chronic bronchial asthma by means of the monoclonal antibodies and humanized antibodies. The present invention is useful for diagnosis or treatment of diseases such as chronic bronchial asthma.

Abstract: The present invention provides monoclonal antibodies and humanized antibodies which react specifically with a human interleukin-5 receptor ? chain. The invention also provides hybridomas and transformants which produce the antibodies, the monoclonal antibodies and humanized antibodies, a method for detecting an interleukin-5 receptor ? chain immunologically by means of these antibodies, as well as a method for diagnosing and treating diseases such as chronic bronchial asthma by means of the monoclonal antibodies and humanized antibodies. The present invention is useful for diagnosis or treatment of diseases such as chronic bronchial asthma.

Abstract: The present invention provides monoclonal antibodies and humanized antibodies which react specifically with a human interleukin-5 receptor ? chain. The invention also provides hybridomas and transformants which produce the antibodies, the monoclonal antibodies and humanized antibodies, a method for detecting an interleukin-5 receptor ? chain immunologically by means of these antibodies, as well as a method for diagnosing and treating diseases such as chronic bronchial asthma by means of the monoclonal antibodies and humanized antibodies. The present invention is useful for diagnosis or treatment of diseases such as chronic bronchial asthma.

Abstract: A paint composition containing a corrosion inhibitor A prepared from porous silica particles, to which Ca ion is bonded by ion-exchange, and a polyphosphate B preferably at an A/B weight ratio of 60/40 to 5/95 and at an A+B ratio of 5-150 parts by weight based on 100 parts by weight of resinous components. A base metal sheet is preferably one pre-treated with a chemical agent containing at least one fluoroacid. Since the polyphosphate B controls dissolution of Ca ion, an effect of Ca ion on corrosion inhibition is maintained over a long term. The painted metal sheet does not put harmful influences on the environment, since it does not contain chromium compounds.

Abstract: The present invention provides monoclonal antibodies and humanized antibodies which react specifically with a human interleukin-5 receptor &agr; chain. The invention also provides hybridomas and transformants which produce the antibodies, the monoclonal antibodies and humanized antibodies, a method for detecting an interleukin-5 receptor &agr; chain immunologically by means of these antibodies, as well as a method for diagnosing and treating diseases such as chronic bronchial asthma by means of the monoclonal antibodies and humanized antibodies. The present invention is useful for diagnosis or treatment of diseases such as chronic bronchial asthma.

Abstract: The present invention provides monoclonal antibodies and humanized antibodies which react specifically with a human interleukin-5 receptor &agr; chain. The invention also provides hybridomas and transformants which produce the antibodies, the monoclonal antibodies and humanized antibodies, a method for detecting an interleukin-5 receptor &agr; chain immunologically by means of these antibodies, as well as a method for diagnosing and treating diseases such as chronic bronchial asthma by means of the monoclonal antibodies and humanized antibodies. The present invention is useful for diagnosis or treatment of diseases such as chronic bronchial asthma.

Abstract: Newly proposed paint composition contains a corrosion inhibitor A prepared from porous silica particles, to which Ca ion is bonded by ion-exchange, and a polyphosphate B preferably at an A/B weight ratio of 60/40 to 5/95 and at an A+B ratio of 5-150 parts by weight based on 100 parts by weight of resinous components. A base metal sheet is preferably one pre-treated with a chemical agent containing at least one fluoroacid. Since the polyphosphate B controls dissolution of Ca ion, an effect of Ca ion on corrosion inhibition is maintained over a long term. The painted metal sheet does not put harmul influences on the environment, since it does not contain chormium compounds.

Abstract: The present invention provides monoclonal antibodies and humanized antibodies which react specifically with a human interleukin-5 receptor .alpha. chain. The invention also provides hybridomas and transformants which produce the antibodies, the monoclonal antibodies and humanized antibodies, a method for detecting an interleukin-5 receptor .alpha. chain immunologically by means of these antibodies, as well as a method for diagnosing and treating diseases such as chronic bronchial asthma by means of the monoclonal antibodies and humanized antibodies. The present invention is useful for diagnosis or treatment of diseases such as chronic bronchial asthma.

Abstract: The invention provides an isolated cDNA sequence coding for murine interleukin 5 receptor, murine secretory interleukin 5 receptor, human interleukin 5 receptor, and human secretory interleukin 5 receptor and products including murine interleukin 5 receptor, murine secretory interleukin 5 receptor, and human interleukin 5 receptor which are produced using the isolated cDNA sequence. These products may be useful for a therapeutic agent for autoimmune disorders and diseases with eosinophilia in which human IL-5 is believed to be involved.

Abstract: The invention provides an isolated cDNA sequence coding for murine interleukin 5 receptor, murine secretory interleukin 5 receptor, human interleukin 5 receptor, and human secretory interleukin 5 receptor and products including murine interleukin 5 receptor, murine secretory interleukin 5 receptor, and human interleukin 5 receptor which are produced using the isolated cDNA sequence. These products may be useful for a therapeutic agent for autoimmune disorders and diseases with eosinophilia in which human IL-5 is believed to be involved.

Abstract: The invention provides an isolated cDNA sequence coding for murine interleukin 5 receptor, murine secretory interleukin 5 receptor, human interleukin 5 receptor, and human secretory interleukin 5 receptor and products including murine interleukin 5 receptor, murine secretory interleukin 5 receptor, and human interleukin 5 receptor which are produced using the isolated cDNA sequence. These products may be useful for a therapeutic agent for autoimmune disorders and diseases with eosinophilia in which human IL-5 is believed to be involved.

Abstract: A cDNA and a chromosomal DNA coding for the human B-cell differentiation factor were provided and the entire nucleotide sequence of said DNAs as well as the entire amino acid sequences of the polypeptide portion of mature human B-cell differentiation factor and the leader peptide were revealed. The method for producing human B-cell differentiation factor by a recombinant gene technology was also provided.

Abstract: The invention provides an isolated cDNA sequence coding for murine interleukin 5 receptor, murine secretory interleukin 5 receptor, human interleukin 5 receptor, and human secretory interleukin 5 receptor and products including murine interleukin 5 receptor, murine secretory interleukin 5 receptor, and human interleukin 5 receptor which are produced using the isolated cDNA sequence. These products may be useful for a therapeutic agent for autoimmune disorders and diseases with eosinophilia in which human IL-5 is believed to be involved.

Abstract: A cDNA and a chromosomal DNA coding for the human B-cell differentiation factor were provided and the entire nucleotide sequence of said DNAs as well as the entire amino acid sequences of the polypeptide portion of mature human B-cell differentiation factor and the leader peptide were revealed. The method for producing human B-cell differentiation factor by a recombinant gene technology was also provided.

Abstract: This invention relates to a shielding material used as a radiation shield of a container containing radioactive wastes. A radiation shield with an excellent heat-transferring property is fabricated from composite particles (A) obtained by coating core particles (a) of radiation-shielding property with a metal (b) of high thermal conductivity. Composite particles are formed into a certain shape of radiation shield by hot-press forming or other forming or packed into the internal space of radioactive waste container or the shield container cavity to compose a radiation shield.

Abstract: Disclosed herein suspension electroplating of fine particles with metal. An electroplating operatively equipped with a cathode and anode is charged with a a metallic ion-containing electrolyte and particles to be electroplated. The particles have a size of from 0.1 to 10 .mu.m. At least a part of the surface of each particle is conductive. Such a stationary circulating flow of a suspension of the particles in the electrolyte is formed in the bath that the particles are maintained in the suspended condition; the suspension is circulated substantially without coming in contact with the anode; the particles may have a chance of colliding with substantially all surface areas of the working surface of the cathode, and are repeatedly brought in collision with the cathode at a velocity with a normal component of from 0.6 to 6.0 m/min; and a particle concentration of the suspension at the time of collision is from 30 to 55% by volume.

Abstract: Disclosed herein suspension electroplating of fine particles with metal. An electroplating operatively equipped with a cathode and anode is charged with a metallic ion-containing electrolyte and particles to be electroplated. The particles have a size of from 0.1 to 10 .mu.m. At least a part of the surface of each particle is conductive. Such a stationary circulating flow of a suspension of the particles in the electrolyte is formed in the bath that the particles are maintained in the suspended condition; the suspension is circulated substantially without coming in contact with the anode; the particles may have a chance of colliding with substantially all surface areas of the working surface of the cathode, and are repeatedly brought in collision with the cathode at a velocity with a normal component of from 0.6 to 6.0 m/min.; and a particle concentration of the suspension at the time of collision is from 30 to 55% by volume.